Kura Oncology (KURA) Amortization of Deferred Charges (2016 - 2026)
Kura Oncology's (KURA) quarterly Amortization of Deferred Charges came in at $106000.0 in Q1 2026, down 20.3% year-on-year from $133000.0 in Q1 2025, and up 2.91% on a QoQ basis from $103000.0 in Q4 2025.
Kura Oncology (KURA) Amortization of Deferred Charges (2016 - 2026) Analysis & Trends
Kura Oncology (KURA) has 7 years of Amortization of Deferred Charges data on file, last reported at $106000.0 in Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges fell 20.3% year-over-year to $106000.0 in Q1 2026; TTM through Mar 2026 was $488000.0, a 8.61% decrease from a year earlier, with the FY2025 full-year figure at $515000.0, down 1.53% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $106000.0, up from $103000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for KURA reached as high as $141000.0 in Q3 2025 and fell as low as $103000.0 in Q4 2025.
- Historically, Amortization of Deferred Charges has averaged $124692.3 across 4 years, with a median of $122000.0 in 2023.
- Across the five-year window, Amortization of Deferred Charges gained 17.65% in 2024 and retreated 26.43% in 2025, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $119000.0 in 2023, then gained by 17.65% to $140000.0 in 2024, then dropped by 26.43% to $103000.0 in 2025, then rose by 2.91% to $106000.0 in 2026.
- Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $106000.0 in Q1 2026, $103000.0 in Q4 2025, and $141000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Kura Oncology | 916.67 Mn | 916.67 Mn | 18.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 106,000.00 |
| Mar 31, 2026 | 106,000.00 |
| Dec 31, 2025 | 103,000.00 |
| Dec 31, 2025 | 103,000.00 |
| Sep 30, 2025 | 141,000.00 |
| Sep 30, 2025 | 141,000.00 |
| Jun 30, 2025 | 138,000.00 |
| Jun 30, 2025 | 138,000.00 |
| Mar 31, 2025 | 133,000.00 |
| Mar 31, 2025 | 133,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Sep 30, 2024 | 134,000.00 |
| Sep 30, 2024 | 134,000.00 |
| Jun 30, 2024 | 127,000.00 |
| Jun 30, 2024 | 127,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Dec 31, 2023 | 119,000.00 |
| Dec 31, 2023 | 119,000.00 |